Related references
Note: Only part of the references are listed.IMiD immunomodulatory compounds block C/EBPβ translation through eIF4E down-regulation resulting in inhibition of MM
Shirong Li et al.
BLOOD (2011)
Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response
Antonia Lopez-Girona et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Evidence of a Role for Activation of Wnt/β-Catenin Signaling in the Resistance of Plasma Cells to Lenalidomide
Chad C. Bjorklund et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Recent advances of IMiDs in cancer therapy
Shirong Li et al.
CURRENT OPINION IN ONCOLOGY (2010)
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
H. Quach et al.
LEUKEMIA (2010)
Identification of a Primary Target of Thalidomide Teratogenicity
Takumi Ito et al.
SCIENCE (2010)
Identification of Copy Number Abnormalities and Inactivating Mutations in Two Negative Regulators of Nuclear Factor-κB Signaling Pathways in Waldenstrom's Macroglobulinemia
Esteban Braggio et al.
CANCER RESEARCH (2009)
Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)
E. Kastritis et al.
LEUKEMIA (2009)
IRF4 addiction in multiple myeloma
Arthur L. Shaffer et al.
NATURE (2008)
Improved survival in multiple myeloma and the impact of novel therapies
Shaji K. Kumar et al.
BLOOD (2008)
The genomic landscapes of human breast and colorectal cancers
Laura D. Wood et al.
SCIENCE (2007)
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma
Paul G. Richardson et al.
BLOOD (2006)
Efficient calculation of interval scores for DNA copy number data analysis
D Lipson et al.
JOURNAL OF COMPUTATIONAL BIOLOGY (2006)
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
SV Rajkumar et al.
BLOOD (2005)
Timeline - The evolution of thalidomide and its IMiD derivatives as anticancer agents
JB Bartlett et al.
NATURE REVIEWS CANCER (2004)
Share Paper
